The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vupparapalli Pavani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.0 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vupparapalli Pavani, a member of the promoter group of Novelix Pharmaceuticals Ltd, has been allotted 3,25,000 equity shares through a preferential allotment on 12 February 2026. This increases her holding from 4,00,000 shares (2.27%) to 7,25,000 shares (3.64%) of the company's total equity share capital. The company's equity share capital rose from Rs. 17.62 crore (1.76 crore shares) to Rs. 19.94 crore (1.99 crore shares) as part of this preferential issue. Total diluted capital after the allotment stands at Rs. 26.69 crore, including 73.35 lakh outstanding convertible warrants. The disclosure was filed under Regulation 29(2) of SEBI Takeover Regulations.
This is a promoter-group share acquisition via preferential allotment, signalling promoter confidence and a strengthening of promoter ownership in the company. For retail investors, this indicates the promoter is putting more skin in the game, though the overall promoter stake remains modest at 3.64% post-allotment.